Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE

NCT04486118 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT04486118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04486118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Phase 2 Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of Centrally Acting, Non-toxic ACE Inhibition in Cognitive Impairment Associated With SLE
Lead sponsor
Northwell Health
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 1, 2021
Completion date
March 1, 2026
Enrollment
36 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus